Disease Indication Strategy for Anti-Fibrotic Drugs

Introduction: Anti-fibrotic drug candidates, prior to entering clinical development, often have a mechanism of action that may be beneficial for treatment of multiple diseases. Early strategic issues...
Learn More

Obesity: Beyond Getting Slim Quick & GLP-1s

Looking Beyond GLP-1s Currently, much of the pharmaceutical industry and up to a quarter of the population of the developed world are captivated by get-slim-quick drugs known as GLP-1 agonists, and...
Learn More

What’s Bugging You? The Next Chapter for Microbiome Drugs

Depending on your perspective, live biotherapeutic products (LBPs) are either a promising, newly emergent class of therapeutic agents that utilize live microorganisms to prevent or treat various...
Learn More

Planning for Pharma Partnering

It's never too early to start For biotechs developing an asset for a pharma partnership, it’s crucial to consider the key deal-success ingredients, in the eyes of a future pharma partner, well in...
Learn More

Cancer Vaccines: Ready for Prime Time or Another False Dawn?

Cancer Vaccines: Ready for Prime Time or Another False Dawn? Moderna and BioNTech recently reported positive early clinical data for mRNA cancer vaccines in combination with PD-1/L1 inhibitors, so...
Learn More

Drug Repurposing: Realities and Roadblocks

Drug Repurposing Market: Realities and Roadblocks We receive a steady stream of enquiries about opportunities in drug repurposing, often from people who see a short, low risk pathway to large...
Learn More

The race is on: after almost six decades, RSV vaccines near the finish line

The COVID-19 pandemic established that, when push comes to shove, successful vaccine development and deployment can be conducted at breakneck speed, even when largely untried and untested...
Learn More

Targeted protein degradation: a new pharmacology paradigm?

Traditional drug development focuses on targeting proteins with a defined binding pocket or active site to regulate protein activity. These strategies have exploited only around 400 of the 4000...
Learn More

Targeted Radiotherapy: The Comeback Kid of Cancer Treatment?

The notion that a systemically administered source of radiation can be usefully directed towards a tumor has been exploited since the 1940s, when radioiodine was introduced as a treatment for thyroid...
Learn More

Could COVID-19 be a catalyst for virtualizing clinical trials?

The virtualization of clinical trials has long been technically feasible, but cultural and regulatory barriers have prevented implementation. With over 1200 clinical trials worldwide being...
Learn More

COVID-19: a catalyst for anti-infective investing?

There has been a persistent call from early stage innovators to shine a spotlight on building anti-infective defenses in light of the looming crisis of antimicrobial resistance (AMR). Unfortunately,...
Learn More

The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More
1 2 3 4
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.